-
公开(公告)号：US09631004B2
公开(公告)日：2017-04-25
申请号：US15215329
申请日：2016-07-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
CPC classification number: A61K38/1825 , A61K38/00 , A61K45/06 , A61K47/60 , A61K47/64 , C07K14/50 , C07K2319/00 , C07K2319/30
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
2.发明授权公开(公告)号：US12247058B2
公开(公告)日：2025-03-11
申请号：US17555633
申请日：2021-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Nucleic acids encoding modified FGF-21 polypeptides, optionally containing at least one non-codon encoding a naturally-encoded amino acid, and vectors and cells containing are provided. These nucleic acids can be used to express the modified FGF-21 polypeptide encoded thereby. The expressed FGF-21 polypeptides may be used as therapeutics, e.g., in the treatment of diseases associated with fibrosis.
-
公开(公告)号：US11642395B2
公开(公告)日：2023-05-09
申请号：US16644839
申请日：2018-09-06
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Edgar Davidson Charles, III , Rose C. Christian , Yi Luo
CPC classification number: A61K38/1825 , A61K45/06 , A61P1/16 , G01N33/6887 , G01N2333/78 , G01N2800/085
Abstract: Provided herein are methods for treating a patient having NASH who has been determined to have a particular threshold level of serum Pro-C3 (e.g., greater than 10 ng/ML) by administering to the patient a modified Fibroblast growth factor 21 (FGF-21) in an amount and with a frequency sufficient to treat NASH. Also provided are methods for monitoring responsiveness of a patient having NASH to treatment with a modified FGF-21, the method comprising: determining the serum Pro-C3 level in a blood sample from the patient obtained during or after treatment, wherein: a decreased serum Pro-C3 level in the blood sample from the patient obtained during or after treatment, as compared to the serum Pro-C3 level in a blood sample from the patient obtained prior to treatment with the modified FGF-21, indicates that the patient is responsive to treatment with the modified FGF-21.
-
公开(公告)号：US11248031B2
公开(公告)日：2022-02-15
申请号：US16455990
申请日：2019-06-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US20190382460A1
公开(公告)日：2019-12-19
申请号：US16455990
申请日：2019-06-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
Patent Agency Ranking
公开(公告)号：US20180243375A1
公开(公告)日：2018-08-30
申请号：US15979881
申请日：2018-05-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
IPC: A61K38/18
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K45/06 , A61K47/60 , A61K47/64 , C07K2319/00 , C07K2319/30
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
7.发明授权Modified FGF-21 polypeptides comprising an internal deletion and uses thereof 有权包含内部缺失的修饰的FGF-21多肽及其用途公开(公告)号：US09434778B2
公开(公告)日：2016-09-06
申请号：US14921796
申请日：2015-10-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
CPC classification number: A61K38/1825 , A61K38/00 , A61K45/06 , A61K47/60 , A61K47/64 , C07K14/50 , C07K2319/00 , C07K2319/30
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
Abstract translation: 提供了修饰的FGF-21多肽及其用途，例如用于治疗与纤维化相关的疾病。 公开了修饰的FGF-21多肽，其含有内部缺失和任选替换的肽，任选地用至少一种非天然编码氨基酸修饰，和/或任选地融合到融合配偶体。
-
公开(公告)号：US20220185856A1
公开(公告)日：2022-06-16
申请号：US17555633
申请日：2021-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US10377806B2
公开(公告)日：2019-08-13
申请号：US15979881
申请日：2018-05-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US10189883B2
公开(公告)日：2019-01-29
申请号：US15460917
申请日：2017-03-16
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.032 seconds)
